Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Data from GEN-003 Phase 2 trial indicate initial course of injections sustains clinical and virologic efficacy for at least 24 months - - End of Phase 2 meeting successfully completed for...
-
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced...
-
CAMBRIDGE, Mass., April 11, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced...
-
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today...
-
CAMBRIDGE, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced...
-
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today...
-
- Positive Phase 2b clinical data confirm attractive profile for GEN-003; expected to start Phase 3 program in 4Q 2017 - - Neoantigen cancer vaccine program on track to file first IND by end of 2017-...
-
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that...
-
- Trial meets statistical significance vs. placebo for multiple clinical endpoints through six months - - End of Phase 2 meeting with FDA expected in Q1 2017 - - Phase 3 launch expected in Q4...
-
- GEN-003 Phase 2b placebo-controlled clinical efficacy data six months after dosing expected in January 2017 - - Announced new research collaborations with Checkmate Pharmaceuticals in...